- Home
- GRAL vs PCRX Comparison
GRAL vs PCRX Comparison
Compare GRAL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- PCRX
- Stock Information
- Founded
- GRAL 2016
- PCRX 2006
- Country
- GRAL United States
- PCRX United States
- Employees
- GRAL N/A
- PCRX N/A
- Industry
- GRAL
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- PCRX Health Care
- Exchange
- GRAL NYSE
- PCRX Nasdaq
- Market Cap
- GRAL 1.3B
- PCRX 1.2B
- IPO Year
- GRAL N/A
- PCRX 2011
- Fundamental
- Price
- GRAL $44.39
- PCRX $23.31
- Analyst Decision
- GRAL Buy
- PCRX Buy
- Analyst Count
- GRAL 3
- PCRX 8
- Target Price
- GRAL $31.50
- PCRX $28.38
- AVG Volume (30 Days)
- GRAL 1.5M
- PCRX 537.5K
- Earning Date
- GRAL 08-12-2025
- PCRX 07-29-2025
- Dividend Yield
- GRAL N/A
- PCRX N/A
- EPS Growth
- GRAL N/A
- PCRX N/A
- EPS
- GRAL N/A
- PCRX N/A
- Revenue
- GRAL $130,711,000.00
- PCRX $702,772,000.00
- Revenue This Year
- GRAL $19.52
- PCRX $7.54
- Revenue Next Year
- GRAL $20.37
- PCRX $10.78
- P/E Ratio
- GRAL N/A
- PCRX N/A
- Revenue Growth
- GRAL 30.47
- PCRX 3.08
- 52 Week Low
- GRAL $12.33
- PCRX $11.16
- 52 Week High
- GRAL $63.99
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- PCRX 37.20
- Support Level
- GRAL N/A
- PCRX $22.82
- Resistance Level
- GRAL N/A
- PCRX $23.83
- Average True Range (ATR)
- GRAL 0.00
- PCRX 0.67
- MACD
- GRAL 0.00
- PCRX -0.05
- Stochastic Oscillator
- GRAL 0.00
- PCRX 20.73
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.